William Blair analyst Andy Hsieh says Genfit (GNFT) and Ipsen’s (IPSEY) top-line results from the Phase III ELATIVE trial of elafibranor in primary biliary cholangitis leave room for CymaBay Therapeutics’ (CBAY) Seladelpar to emerge as best-in-class. The analyst is “encouraged” by the numerically higher rate of cholestasis response for seladelpar versus elafibranor. Furthermore, the firm is optimistic that seladelpar could show a statistically significant reduction in itch. Blair believes a “competitive overhang” on CymaBay shares has now been removed and keeps an Outperform rating on the name.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CBAY: